Zynerba Pharmaceuticals Inc (ZYNE.OQ)
20 Mar 2018
* ZYNERBA PHARMACEUTICALS REPORTS FOURTH QUARTER AND YEAR END 2017 FINANCIAL RESULTS AND OPERATIONAL HIGHLIGHTS
BRIEF-Zynerba Pharma Plans To Conduct Single Pivotal Study Of ZYN002 In Fragile X Syndrome To Support NDA Filing
* ZYNERBA PHARMACEUTICALS ANNOUNCES POSITIVE MEETING WITH U.S. FOOD AND DRUG ADMINISTRATION AND PLANS TO CONDUCT A SINGLE PIVOTAL STUDY OF ZYN002 IN FRAGILE X SYNDROME TO SUPPORT AN NDA FILING
BRIEF-Zynerba Pharmaceuticals Inc Plans To Initiate Phase 2 Development Of ZYN001 In Tourette Syndrome By Year End
* ZYNERBA PHARMACEUTICALS PROVIDES 2018 CLINICAL AND CORPORATE UPDATE
* Zynerba Pharmaceuticals reports third quarter 2017 financial results and operational highlights
Zynerba Pharmaceuticals Inc said on Thursday its cannabis-derived gel to treat genetic disorder Fragile X syndrome succeeded in significantly reducing symptoms such as anxiety in a mid-stage study.
* Shares rise nearly 60 percent (Adds details on company's plans, analyst comment, updates share price)
BRIEF-Zynerba Pharmaceuticals announces positive top line results in ZYN002 open label Phase 2 FAB-C study
* Zynerba Pharmaceuticals announces positive top line results in ZYN002 open label Phase 2 FAB-C study in children with Fragile X syndrome
Sept 28 Zynerba Pharmaceuticals Inc said on Thursday its cannabis-based gel succeeded in a mid-stage study of patients with Fragile X syndrome, a genetic disorder that causes learning disabilities.